NCT05395013 (NEOSTENT) is a clinical trial in Common Bile Duct Stricture, sponsored by Azienda Unità Sanitaria Locale della Romagna.

Who is sponsoring NCT05395013?

NCT05395013 is sponsored by Azienda Unità Sanitaria Locale della Romagna.

What condition does NCT05395013 study?

NCT05395013 studies Common Bile Duct Stricture, Jaundice; Malignant.

Is NCT05395013 still recruiting?

NCT05395013 is currently completed. Last updated 7 June 2022.

Last reviewed 2022-06-07 · How we verify

NCT05395013: NEOSTENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Plastic, Covered and Uncovered Self-expandable Metal Stents in the Treatment of Malignant Biliary Obstructions (NEOSTENT)

Completed Last updated 7 June 2022

What this trial tests

trial in Common Bile Duct Stricture in 3,149 participants. Completed in 31 May 2022.

Timeline

1 November 2021

Primary endpoint
31 May 2022

31 May 2022

Quick facts

Lead sponsor	Azienda Unità Sanitaria Locale della Romagna
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,149
Start date	1 November 2021
Primary completion	31 May 2022
Estimated completion	31 May 2022
Sites	1 location across Italy

Conditions studied

Common Bile Duct Stricture — all drugs for Common Bile Duct Stricture →
Jaundice; Malignant — all drugs for Jaundice; Malignant →

Sponsor

Azienda Unità Sanitaria Locale della Romagna

Who can join

18 and older, any sex, with Common Bile Duct Stricture or Jaundice; Malignant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the efficacy and safety of the various types of stents available for biliary drainage in patients with neoplastic stenosis of the common bile duct and to evaluate the adherence to the current guidelines available.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Azienda Unità Sanitaria Locale della Romagna trials

Trials by the same sponsor.

NCT05913453 — Technical Failure During Colorectal Endoscopic Full Thickness Resection (EFTR): The "Through Thick and Thin" Study · completed
NCT06115564 — Microbiological Assessment of Bile in Patients Undergone to Endoscopic Retrograde Cholangiography (ERCP): the "Microbile · unknown
NCT05690412 — Efficacy and Safety of Endoscopic Papillectomy in the Treatment of Ampullary Neoplasms. · unknown
NCT06965036 — Risk Factors and Outcomes of Ischemic Stroke Associated With Tandem or Isolated Cervical Artery Occlusion in Anterior an · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05395013 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Unità Sanitaria Locale della Romagna
Last refreshed: 7 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05395013.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing